Jennifer Taylor-Cousar
Concepts (346)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 129 | 2026 | 1118 | 23.370 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 78 | 2026 | 358 | 15.400 |
Why?
| | Quinolones | 38 | 2026 | 185 | 9.520 |
Why?
| | Aminophenols | 49 | 2026 | 188 | 9.320 |
Why?
| | Benzodioxoles | 35 | 2026 | 145 | 6.930 |
Why?
| | Chloride Channel Agonists | 30 | 2026 | 95 | 4.990 |
Why?
| | Indoles | 28 | 2026 | 479 | 4.320 |
Why?
| | Sinusitis | 12 | 2025 | 237 | 3.720 |
Why?
| | Rhinitis | 10 | 2025 | 173 | 2.920 |
Why?
| | Pyridines | 23 | 2026 | 612 | 2.820 |
Why?
| | Pyrazoles | 25 | 2026 | 499 | 2.740 |
Why?
| | Pyrrolidines | 20 | 2026 | 114 | 2.720 |
Why?
| | Olfaction Disorders | 8 | 2025 | 70 | 2.230 |
Why?
| | Drug Combinations | 28 | 2026 | 376 | 2.220 |
Why?
| | Aminopyridines | 6 | 2025 | 125 | 1.990 |
Why?
| | Mutation | 34 | 2024 | 4106 | 1.840 |
Why?
| | Membrane Transport Modulators | 3 | 2020 | 7 | 1.790 |
Why?
| | Fetal Therapies | 2 | 2026 | 47 | 1.780 |
Why?
| | Pongo pygmaeus | 3 | 2024 | 7 | 1.760 |
Why?
| | Pregnancy Complications | 6 | 2025 | 590 | 1.720 |
Why?
| | Ape Diseases | 3 | 2024 | 7 | 1.520 |
Why?
| | Reproductive Health | 9 | 2024 | 92 | 1.330 |
Why?
| | Humans | 138 | 2026 | 143821 | 1.270 |
Why?
| | Azithromycin | 7 | 2021 | 104 | 1.250 |
Why?
| | Quality of Life | 18 | 2026 | 3142 | 1.220 |
Why?
| | Pregnancy Outcome | 6 | 2024 | 466 | 1.220 |
Why?
| | Pregnancy | 22 | 2026 | 7154 | 1.200 |
Why?
| | Adult | 69 | 2026 | 40129 | 1.100 |
Why?
| | Respiratory System Agents | 2 | 2020 | 23 | 1.080 |
Why?
| | Parents | 5 | 2024 | 1414 | 1.070 |
Why?
| | Sexual Health | 6 | 2025 | 67 | 1.060 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2025 | 43 | 1.060 |
Why?
| | Female | 81 | 2026 | 77570 | 1.000 |
Why?
| | Quinolines | 9 | 2026 | 185 | 0.990 |
Why?
| | Paranasal Sinuses | 5 | 2024 | 85 | 0.930 |
Why?
| | Pseudomonas Infections | 9 | 2024 | 218 | 0.860 |
Why?
| | Chronic Disease | 15 | 2026 | 1826 | 0.850 |
Why?
| | Drug Approval | 3 | 2024 | 88 | 0.850 |
Why?
| | Pregnancy Rate | 3 | 2021 | 70 | 0.830 |
Why?
| | Fetal Diseases | 1 | 2026 | 191 | 0.820 |
Why?
| | Respiratory Mucosa | 2 | 2025 | 326 | 0.820 |
Why?
| | Anti-Bacterial Agents | 12 | 2024 | 1901 | 0.810 |
Why?
| | Pongo | 2 | 2021 | 7 | 0.810 |
Why?
| | Genetic Therapy | 5 | 2026 | 322 | 0.780 |
Why?
| | Treatment Outcome | 25 | 2026 | 11459 | 0.750 |
Why?
| | Prospective Studies | 18 | 2026 | 7900 | 0.720 |
Why?
| | Male | 63 | 2026 | 71569 | 0.700 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 1088 | 0.670 |
Why?
| | Lung Transplantation | 1 | 2024 | 336 | 0.670 |
Why?
| | Aerosols | 2 | 2026 | 183 | 0.670 |
Why?
| | Glucose Intolerance | 2 | 2025 | 145 | 0.660 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.660 |
Why?
| | Sputum | 6 | 2026 | 314 | 0.640 |
Why?
| | Sweat | 9 | 2025 | 48 | 0.630 |
Why?
| | Compassionate Use Trials | 1 | 2019 | 7 | 0.620 |
Why?
| | Smell | 4 | 2025 | 132 | 0.610 |
Why?
| | Young Adult | 29 | 2026 | 13914 | 0.600 |
Why?
| | Lung | 9 | 2023 | 4143 | 0.600 |
Why?
| | Fertility | 3 | 2025 | 167 | 0.580 |
Why?
| | Pseudomonas aeruginosa | 9 | 2022 | 349 | 0.580 |
Why?
| | Transcriptome | 1 | 2025 | 1047 | 0.580 |
Why?
| | Precision Medicine | 2 | 2021 | 450 | 0.580 |
Why?
| | Glucose Tolerance Test | 3 | 2026 | 376 | 0.560 |
Why?
| | Breast Feeding | 3 | 2025 | 444 | 0.550 |
Why?
| | Forced Expiratory Volume | 11 | 2023 | 493 | 0.540 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 258 | 0.520 |
Why?
| | Drug Monitoring | 6 | 2020 | 394 | 0.520 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 28 | 0.510 |
Why?
| | Adolescent | 30 | 2026 | 22233 | 0.500 |
Why?
| | Child | 24 | 2025 | 22440 | 0.500 |
Why?
| | Rifampin | 1 | 2017 | 81 | 0.490 |
Why?
| | Leukocyte Elastase | 2 | 2026 | 76 | 0.490 |
Why?
| | Pongo abelii | 1 | 2016 | 1 | 0.490 |
Why?
| | Biomedical Research | 3 | 2024 | 709 | 0.480 |
Why?
| | Chlorides | 8 | 2025 | 136 | 0.470 |
Why?
| | Surveys and Questionnaires | 12 | 2026 | 6004 | 0.460 |
Why?
| | Sildenafil Citrate | 2 | 2014 | 60 | 0.450 |
Why?
| | Bronchiectasis | 1 | 2016 | 112 | 0.430 |
Why?
| | Tobramycin | 5 | 2019 | 54 | 0.430 |
Why?
| | Infertility, Male | 2 | 2025 | 73 | 0.420 |
Why?
| | Double-Blind Method | 11 | 2026 | 2017 | 0.400 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2020 | 667 | 0.400 |
Why?
| | Respiratory Function Tests | 6 | 2025 | 570 | 0.370 |
Why?
| | Lactation | 3 | 2022 | 193 | 0.360 |
Why?
| | Contraception Behavior | 2 | 2025 | 107 | 0.350 |
Why?
| | Genotype | 8 | 2025 | 1837 | 0.340 |
Why?
| | Homozygote | 4 | 2021 | 201 | 0.340 |
Why?
| | Contraception | 2 | 2025 | 166 | 0.330 |
Why?
| | Drug Interactions | 4 | 2020 | 398 | 0.310 |
Why?
| | International Cooperation | 2 | 2020 | 197 | 0.300 |
Why?
| | Alleles | 8 | 2025 | 883 | 0.300 |
Why?
| | Respiratory Muscles | 1 | 2009 | 35 | 0.300 |
Why?
| | Hypoventilation | 1 | 2009 | 18 | 0.300 |
Why?
| | Animals | 13 | 2026 | 38140 | 0.290 |
Why?
| | Blood Glucose | 3 | 2025 | 2325 | 0.280 |
Why?
| | ABO Blood-Group System | 1 | 2009 | 58 | 0.280 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2026 | 29 | 0.280 |
Why?
| | Parenting | 2 | 2023 | 322 | 0.280 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1047 | 0.270 |
Why?
| | Tomography, X-Ray Computed | 4 | 2022 | 2782 | 0.260 |
Why?
| | Needs Assessment | 2 | 2020 | 395 | 0.250 |
Why?
| | Middle Aged | 22 | 2026 | 35630 | 0.250 |
Why?
| | Asthma | 3 | 2024 | 1915 | 0.250 |
Why?
| | Quinuclidines | 1 | 2026 | 11 | 0.240 |
Why?
| | Sexual Behavior | 3 | 2025 | 490 | 0.240 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 618 | 0.240 |
Why?
| | United States | 11 | 2025 | 15602 | 0.240 |
Why?
| | Dependovirus | 1 | 2026 | 78 | 0.230 |
Why?
| | Phenylpropionates | 1 | 2025 | 27 | 0.230 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 127 | 0.230 |
Why?
| | Airway Remodeling | 1 | 2025 | 71 | 0.220 |
Why?
| | Off-Label Use | 1 | 2025 | 49 | 0.220 |
Why?
| | Oligonucleotides, Antisense | 1 | 2025 | 114 | 0.220 |
Why?
| | Pyrroles | 1 | 2026 | 213 | 0.220 |
Why?
| | Biomarkers | 6 | 2026 | 4248 | 0.220 |
Why?
| | Organoids | 1 | 2026 | 135 | 0.210 |
Why?
| | Fertility Preservation | 1 | 2024 | 53 | 0.210 |
Why?
| | Minimal Clinically Important Difference | 1 | 2023 | 27 | 0.210 |
Why?
| | Infant, Newborn | 4 | 2024 | 6362 | 0.200 |
Why?
| | Food Preferences | 1 | 2025 | 126 | 0.200 |
Why?
| | Orphan Drug Production | 1 | 2023 | 5 | 0.200 |
Why?
| | Pregnancy, Unplanned | 2 | 2023 | 48 | 0.200 |
Why?
| | C-Reactive Protein | 2 | 2018 | 419 | 0.200 |
Why?
| | Sexually Transmitted Diseases | 1 | 2025 | 168 | 0.200 |
Why?
| | Patient Selection | 2 | 2019 | 695 | 0.200 |
Why?
| | Intestines | 1 | 2026 | 354 | 0.190 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 114 | 0.190 |
Why?
| | Ion Transport | 2 | 2021 | 63 | 0.190 |
Why?
| | Respiratory Tract Diseases | 1 | 2024 | 181 | 0.190 |
Why?
| | Neonatal Screening | 1 | 2024 | 175 | 0.190 |
Why?
| | Body Height | 1 | 2023 | 202 | 0.190 |
Why?
| | Puberty | 1 | 2023 | 154 | 0.180 |
Why?
| | Azabicyclo Compounds | 1 | 2021 | 7 | 0.180 |
Why?
| | Epoxide Hydrolases | 1 | 2021 | 13 | 0.180 |
Why?
| | Enzyme Activators | 1 | 2021 | 9 | 0.180 |
Why?
| | Inflammation | 3 | 2026 | 2893 | 0.170 |
Why?
| | Benzoates | 1 | 2021 | 49 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2030 | 0.170 |
Why?
| | Retrospective Studies | 11 | 2026 | 16754 | 0.170 |
Why?
| | Vascular Stiffness | 1 | 2026 | 462 | 0.170 |
Why?
| | RNA, Messenger | 3 | 2022 | 2847 | 0.170 |
Why?
| | Men's Health | 1 | 2020 | 6 | 0.170 |
Why?
| | Cyclopropanes | 3 | 2026 | 80 | 0.170 |
Why?
| | Infertility | 1 | 2021 | 55 | 0.170 |
Why?
| | Endoscopy | 4 | 2024 | 326 | 0.170 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 394 | 0.160 |
Why?
| | Women's Rights | 1 | 2020 | 4 | 0.160 |
Why?
| | Communicable Disease Control | 1 | 2020 | 86 | 0.160 |
Why?
| | Disease Progression | 5 | 2020 | 2871 | 0.160 |
Why?
| | Virulence Factors | 2 | 2014 | 170 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 2 | 2025 | 872 | 0.150 |
Why?
| | Aztreonam | 2 | 2016 | 11 | 0.150 |
Why?
| | Cataract | 1 | 2022 | 237 | 0.150 |
Why?
| | Colistin | 1 | 2019 | 10 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2025 | 1402 | 0.150 |
Why?
| | Medication Therapy Management | 1 | 2020 | 72 | 0.150 |
Why?
| | Sexism | 1 | 2020 | 70 | 0.150 |
Why?
| | Epithelial Cells | 3 | 2026 | 1128 | 0.150 |
Why?
| | Neutrophils | 3 | 2016 | 1144 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2024 | 5316 | 0.150 |
Why?
| | Receptors, Interleukin-8B | 1 | 2018 | 23 | 0.150 |
Why?
| | Research Design | 1 | 2024 | 1121 | 0.140 |
Why?
| | Health Status | 1 | 2023 | 821 | 0.140 |
Why?
| | Administration, Oral | 1 | 2020 | 841 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2926 | 0.130 |
Why?
| | Mental Health | 1 | 2024 | 774 | 0.130 |
Why?
| | Pyrimidines | 1 | 2021 | 536 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 465 | 0.130 |
Why?
| | Insulin Resistance | 1 | 2026 | 1255 | 0.130 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.130 |
Why?
| | Pregnancy, High-Risk | 1 | 2017 | 14 | 0.130 |
Why?
| | HEK293 Cells | 1 | 2020 | 748 | 0.130 |
Why?
| | Leukocytes | 1 | 2018 | 293 | 0.130 |
Why?
| | Risk Assessment | 3 | 2021 | 3556 | 0.130 |
Why?
| | Biological Availability | 1 | 2017 | 141 | 0.120 |
Why?
| | Respiratory Tract Infections | 1 | 2021 | 395 | 0.120 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2948 | 0.120 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 68 | 0.120 |
Why?
| | Research | 1 | 2020 | 426 | 0.120 |
Why?
| | Risk Adjustment | 1 | 2017 | 84 | 0.120 |
Why?
| | Prognosis | 2 | 2022 | 4210 | 0.120 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 243 | 0.120 |
Why?
| | Albuterol | 1 | 2016 | 74 | 0.120 |
Why?
| | Recovery of Function | 1 | 2020 | 695 | 0.120 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1817 | 0.120 |
Why?
| | Pharmacogenetics | 1 | 2017 | 170 | 0.120 |
Why?
| | Health Services Accessibility | 2 | 2024 | 1078 | 0.110 |
Why?
| | Attitude of Health Personnel | 1 | 2023 | 1174 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 500 | 0.110 |
Why?
| | Interferons | 1 | 2016 | 193 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2016 | 223 | 0.110 |
Why?
| | Bronchodilator Agents | 1 | 2016 | 194 | 0.110 |
Why?
| | Pilot Projects | 2 | 2020 | 1851 | 0.110 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2014 | 35 | 0.110 |
Why?
| | Child, Preschool | 3 | 2024 | 11630 | 0.110 |
Why?
| | Machine Learning | 1 | 2020 | 573 | 0.110 |
Why?
| | Staphylococcal Infections | 1 | 2019 | 390 | 0.110 |
Why?
| | Metalloproteases | 1 | 2014 | 41 | 0.110 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 408 | 0.110 |
Why?
| | Quorum Sensing | 1 | 2014 | 71 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2015 | 2407 | 0.100 |
Why?
| | Body Mass Index | 2 | 2023 | 2439 | 0.100 |
Why?
| | Preconception Care | 2 | 2025 | 50 | 0.100 |
Why?
| | Administration, Inhalation | 3 | 2022 | 592 | 0.100 |
Why?
| | Neutrophil Activation | 1 | 2013 | 85 | 0.090 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 62 | 0.090 |
Why?
| | Wound Infection | 1 | 2013 | 42 | 0.090 |
Why?
| | Condoms | 2 | 2025 | 100 | 0.090 |
Why?
| | Cellular Structures | 1 | 2011 | 6 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1638 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 115 | 0.090 |
Why?
| | Drug Therapy, Combination | 3 | 2021 | 1032 | 0.080 |
Why?
| | Extracellular Space | 1 | 2011 | 132 | 0.080 |
Why?
| | Microbial Viability | 1 | 2011 | 92 | 0.080 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 706 | 0.080 |
Why?
| | Patient Admission | 1 | 2012 | 206 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 580 | 0.080 |
Why?
| | Risk Factors | 3 | 2020 | 10623 | 0.080 |
Why?
| | Infant | 1 | 2024 | 9885 | 0.080 |
Why?
| | Survival Rate | 2 | 2018 | 2034 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5761 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2098 | 0.070 |
Why?
| | Sex Factors | 2 | 2026 | 2078 | 0.070 |
Why?
| | Blood Group Antigens | 1 | 2009 | 15 | 0.070 |
Why?
| | Aged | 5 | 2024 | 25615 | 0.070 |
Why?
| | Mucus | 1 | 2009 | 78 | 0.070 |
Why?
| | ADP Ribose Transferases | 1 | 2007 | 9 | 0.070 |
Why?
| | Mass Screening | 1 | 2016 | 1325 | 0.070 |
Why?
| | Exotoxins | 1 | 2007 | 16 | 0.070 |
Why?
| | Inpatients | 1 | 2012 | 528 | 0.070 |
Why?
| | Burns | 1 | 2013 | 365 | 0.070 |
Why?
| | Furin | 1 | 2007 | 14 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 18 | 0.070 |
Why?
| | Cyclic GMP | 1 | 2007 | 92 | 0.060 |
Why?
| | Time Factors | 3 | 2024 | 7068 | 0.060 |
Why?
| | Bacterial Toxins | 1 | 2007 | 108 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2620 | 0.060 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 184 | 0.060 |
Why?
| | Phenotype | 1 | 2015 | 3183 | 0.060 |
Why?
| | Sulfones | 1 | 2007 | 127 | 0.060 |
Why?
| | Survivors | 1 | 2010 | 513 | 0.060 |
Why?
| | Registries | 3 | 2023 | 2242 | 0.060 |
Why?
| | Respiratory System | 1 | 2007 | 159 | 0.060 |
Why?
| | Transduction, Genetic | 1 | 2026 | 136 | 0.060 |
Why?
| | Transgenes | 1 | 2026 | 188 | 0.060 |
Why?
| | Rats | 2 | 2026 | 5609 | 0.060 |
Why?
| | Rats, Inbred F344 | 1 | 2026 | 269 | 0.060 |
Why?
| | Quinoxalines | 1 | 2025 | 64 | 0.060 |
Why?
| | Pulse Wave Analysis | 1 | 2026 | 245 | 0.060 |
Why?
| | Genetic Vectors | 1 | 2026 | 342 | 0.050 |
Why?
| | European Union | 1 | 2024 | 11 | 0.050 |
Why?
| | Piperazines | 1 | 2007 | 394 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2009 | 706 | 0.050 |
Why?
| | Reproductive Health Services | 1 | 2023 | 18 | 0.050 |
Why?
| | Developing Countries | 1 | 2026 | 313 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2095 | 0.050 |
Why?
| | Standard of Care | 1 | 2024 | 80 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 200 | 0.050 |
Why?
| | Nose | 1 | 2023 | 65 | 0.050 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2024 | 62 | 0.050 |
Why?
| | Cell Separation | 2 | 2016 | 311 | 0.050 |
Why?
| | Deoxyribonuclease I | 1 | 2022 | 38 | 0.050 |
Why?
| | Saline Solution, Hypertonic | 1 | 2022 | 42 | 0.050 |
Why?
| | Rare Diseases | 1 | 2023 | 113 | 0.050 |
Why?
| | Vasodilation | 1 | 2026 | 522 | 0.050 |
Why?
| | Sex Education | 1 | 2022 | 34 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 270 | 0.050 |
Why?
| | Hot Flashes | 1 | 2023 | 88 | 0.050 |
Why?
| | Contraceptive Agents | 1 | 2022 | 65 | 0.040 |
Why?
| | Psychometrics | 1 | 2026 | 728 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2014 | 371 | 0.040 |
Why?
| | Iron | 1 | 2024 | 355 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2009 | 2167 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2024 | 315 | 0.040 |
Why?
| | Biofilms | 2 | 2014 | 278 | 0.040 |
Why?
| | Nutritional Status | 1 | 2023 | 351 | 0.040 |
Why?
| | Genetic Counseling | 1 | 2021 | 81 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 294 | 0.040 |
Why?
| | Attitude | 1 | 2022 | 257 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 865 | 0.040 |
Why?
| | Longevity | 1 | 2021 | 174 | 0.040 |
Why?
| | Menopause | 1 | 2023 | 316 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2026 | 965 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2022 | 1355 | 0.040 |
Why?
| | Incidence | 1 | 2026 | 2845 | 0.040 |
Why?
| | Tetraspanin 30 | 1 | 2018 | 10 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 592 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2022 | 828 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 170 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 23 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 475 | 0.030 |
Why?
| | Ecosystem | 1 | 2023 | 585 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2012 | 2590 | 0.030 |
Why?
| | trans-Golgi Network | 2 | 2007 | 15 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2024 | 700 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2026 | 3392 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2016 | 3614 | 0.030 |
Why?
| | Gene Deletion | 1 | 2018 | 388 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2007 | 164 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 322 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 41 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2018 | 4172 | 0.030 |
Why?
| | Genetic Variation | 1 | 2021 | 990 | 0.030 |
Why?
| | Leadership | 1 | 2020 | 404 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 184 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2023 | 1322 | 0.030 |
Why?
| | Medication Adherence | 1 | 2018 | 519 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4578 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 81 | 0.030 |
Why?
| | Depression | 1 | 2024 | 1520 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 957 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1057 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1358 | 0.020 |
Why?
| | Ciprofloxacin | 1 | 2013 | 26 | 0.020 |
Why?
| | Cohort Studies | 1 | 2023 | 5861 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1508 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 345 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 207 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 364 | 0.020 |
Why?
| | Cell Line | 2 | 2007 | 2906 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 29 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 213 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 457 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 395 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 379 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 543 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8130 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2097 | 0.020 |
Why?
| | Insulin Infusion Systems | 1 | 2012 | 479 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 23 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2007 | 84 | 0.020 |
Why?
| | Epithelial Sodium Channels | 1 | 2007 | 21 | 0.020 |
Why?
| | Guanylate Cyclase | 1 | 2007 | 39 | 0.020 |
Why?
| | Sodium | 1 | 2007 | 198 | 0.020 |
Why?
| | Purines | 1 | 2007 | 188 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 563 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2007 | 1054 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 481 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2012 | 1393 | 0.010 |
Why?
| | Mice | 2 | 2013 | 18421 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2007 | 903 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4553 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2182 | 0.010 |
Why?
| | Insulin | 1 | 2012 | 2502 | 0.010 |
Why?
| | Macrophages | 1 | 2007 | 1508 | 0.010 |
Why?
| | Signal Transduction | 1 | 2007 | 5241 | 0.010 |
Why?
|
|
Taylor-Cousar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|